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Health data poverty: an assailable barrier to equitable digital 
health care
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Data-driven digital health technologies have the power to transform health care. If these tools could be sustainably 
delivered at scale, they might have the potential to provide everyone, everywhere, with equitable access to expert-level 
care, narrowing the global health and wellbeing gap. Conversely, it is highly possible that these transformative 
technologies could exacerbate existing health-care inequalities instead. In this Viewpoint, we describe the problem of 
health data poverty: the inability for individuals, groups, or populations to benefit from a discovery or innovation due 
to a scarcity of data that are adequately representative. We assert that health data poverty is a threat to global health 
that could prevent the benefits of data-driven digital health technologies from being more widely realised and might 
even lead to them causing harm. We argue that the time to act is now to avoid creating a digital health divide that 
exacerbates existing health-care inequalities and to ensure that no one is left behind in the digital era.
Introduction
Developments in artificial intelligence, and particularly 
machine learning, have shown the power that data-
driven digital health technologies have to transform 
health care.1 If these tools could be sustainably delivered 
at scale, they have the potential to provide everyone, 
everywhere, with equitable access to expert-level care—in 
line with the vision set out in WHO’s Global Strategy on 
Digital Health2—and thereby narrow the global health 
and wellbeing gap. Conversely, it is highly possible 
that these transformative technologies could exacerbate 
existing health-care inequalities instead.3–8
In this Viewpoint, we describe the problem of health 
data poverty. We then discuss potential solutions to the 
problem, notably investing in inclusive and representative 
health datasets to support equitable discovery and 
innovation in digital health care.
The problem: health data poverty and its risk of 
creating a digital health divide
We define health data poverty as the inability for 
individuals, groups, or populations to benefit from a 
discovery or innovation due to insufficient data that are 
adequately representative. To properly understand the 
problem of health data poverty, and, by extension, the 
solutions, it is important to understand what health data 
are, how health data are used, and what health data 
disparities are.
First, what are health data? Health data have been 
defined as information relating to the past, current, or 
future physical or mental health status of a person.9 
Health data include any of the clinical, biochemical, 
radiological, molecular, and pathological information 
pertaining to a patient that is captured by health-care 
professionals and, increasingly, digitally recorded and 
stored in electronic patient health records.10 Health data 
also include any of the health-related information that is 
captured by patients themselves, by using sensors and a 
growing range of smart devices, and stored in smart-
phones, tablets, computers, and cloud-based repositories.10 
The digitalisation of health care has meant that humans 
today are amassing health data at astronomical rates, with 
estimates putting the total volume of health data in 2020 
at 2314 exabytes—where one exabyte is equal to 1 billion 
gigabytes.11
Second, how are health data used? Health data are used 
to benefit patients and the public, and the use of health 
data can be classified as either primary or secondary. 
The primary (direct) use is where health data are used to 
deliver health care to the individual from whom they 
were collected.12 Here, health data inform health-care 
professionals when making diagnoses and decisions 
relating to an individual’s care. The secondary (indirect) 
use is where health data are used to improve health care 
and health-care services for a population.12 In this instance, 
health data relating to many different people are pooled 
together to create large health datasets that can be used to 
evaluate multiple hypotheses related to improving health 
care. Appropriate interrogation of health data can improve 
understanding of disease and disability, identify better 
ways to predict and diagnose illness, develop new 
treatments and technologies, monitor safety, plan services, 
and evaluate policies. The secondary use of health data 
has been instrumental in driving discovery and innovation 
in the digital age. As the medical community attempts to 
shift from reactive care to proactive and preventive care, 
there is a move to integrate predictive devices into daily 
life. This process is contributing to a future of health care 
that is more preventive, predictive, and personalised, and 
it is this use that is most relevant to health data poverty.
Third, what are health data disparities? Health data 
disparities are systematic differences in the quantity or 
quality, or both, of health data representing different 
individuals, groups, or populations. Data disparities have 
been shown within and between populations as well as 
across different demographics, disciplines, and diseases. 
For example, as of 2018, individuals included in genome-
wide association studies were 78% European, 10% Asian, 
2% African, 1% Hispanic, and less than 1% all other 
ethnic groups, leading to the conclusion that European 
bias in human genetic studies is “both scientifically 
damaging and unfair”.13 Similarly, the sample of 
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individuals whose data make up UK Biobank has been 
shown to be much healthier than the general popula-
tion, with underrepresentation of individuals with 
socioeconomic deprivation and from particular ethnic 
backgrounds.14 However, disparities are not solely limited 
to genetics datasets. Regarding imaging, it was found 
that, across multiple medical specialities in the USA, 
deep learning algorithms that perform image-based 
diagnostic tasks were disproportionately trained on data 
from California, Massachusetts, and New York, with little 
to no representation from the remaining 47 states and 
their populations.15 And, focusing just on the field of 
ophthalmology, a global review of ophthalmic imaging 
datasets revealed disparities in the representation of 
different populations and disease groups in publicly 
available health data repositories.16
These imbalances lead to datasets that underrepresent 
key segments of the overall population. As these same 
datasets are used to develop and validate digital health 
technologies, a possible extreme scenario is that data-
driven interventions are safe and effective for some 
people, but dangerous and ineffective for others. This 
scenario is possible because these tools are entirely 
dependent on the data that are used to develop and 
validate them and can be highly sensitive to fundamental 
characteristics including age, sex, ethnicity, environment, 
and potentially many others. Therefore, people who are 
underrepresented might be unable to benefit from these 
data-driven interventions, and could even be harmed 
by them. This is a well recognised and common cause of 
the limited usability of some artificial intelligence and 
machine learning algorithms beyond health care. For 
example, this is the reason why automatic speech 
recognition systems such as Alexa and Siri can have high 
failure rates when applied to diverse user groups.17
In cases in which a data-driven digital health 
technology underperforms when applied to individuals 
from an underrepresented group, individuals from the 
underrepresented group can be considered to be health 
data poor. This lack of generalisability of discoveries 
and innovations across peoples and populations due to 
underrepresentation is also rife in non-digital contexts. 
It is remarkable how frequently tests, therapeutics, and 
other interventions are not evaluated in children,18 
women (especially pregnant women),19,20 people from 
minority ethnic groups,21 and older people,22 and 
indeed, this situation has recently been highlighted by 
the US Food and Drug Administration in their guidance 
for diversity in clinical trials.23 Similarly, it is surprising 
how infrequently the so-called normal ranges of 
physiological parameters take into account age, sex, 
and ethnicity.24 But it is in the accelerating world of 
digital health that health data poverty will cause most 
direct and indirect harm, and that is our focus in this 
Viewpoint.
Evidence is already accumulating of the negative 
consequences of health data poverty in the context 
of digital health. In 2019, Tomašev and colleagues25 
described a deep learning algorithm for predicting acute 
kidney injury in adults. Only 6·4% of the data in the 
training dataset was derived from female patients and, 
as expected, the model was found to underperform in 
this group. This is a good example of gender-related 
health data disparities causing relative health data 
poverty in women. The authors acknowledge that 
“validating the predictive performance of the proposed 
system on a general population would require training 
and evaluating the model on additional representative 
datasets”.25 The impact of health data poverty is only 
going to increase as more data-driven technologies 
become mainstream. An area of intense interest in 
digital health is automated skin lesion diagnosis, but 
there are already concerns about the failure of these 
digital health applications to be inclusive, due in part to 
the non-representativeness of the training data.26 It 
should, however, be noted that the failures of digital 
health in this regard mimic long-standing failures of 
humans, with provision of training materials for 
dermatologists being overwhelmingly from paler skin 
types,27 and with human diagnostic performance being 
consistently worse in darker skinned patients.28 
Although examples such as these might be relatively 
obvious, there could be other applications in which 
the underperformance of data-driven technologies in 
particular poorly represented groups will not be detected 
unless this is specifically looked for.
It is encouraging that the risks associated with the 
use of non-representative datasets,4,5 as well as the 
associated ethical issues that can arise throughout 
the develop ment pipeline of a digital health technology,3 
are being increasingly recognised. The value of the 
term health data poverty is to recognise this data paucity 
for what it is: a poverty that is born out of existing 
inequalities and could foster further inequality. There 
is a risk that, rather than narrowing the health and 
wellbeing gap around the world, data-driven solutions, 
such as artificial intelligence systems, will create a 
digital health divide that leaves us with a two-tier health 
system of digital haves and digital have-nots. The digital 
divide cannot be thought of as simply a matter of 
access to technologies, but rather as an issue that runs 
through the whole digital pathway, starting with the 
data foundation on which these technologies are 
dependent. If health-care systems wish to embrace the 
advantages of digital health without perpetuating or 
exacerbating existing health inequalities, they must 
recognise and address the threat of health data poverty.
Addressing health data poverty: where do we 
start?
As with other forms of poverty, health data poverty is 
complex and not amenable to a single, simple solution. 
Our purpose here is to raise awareness of this important 
issue, to highlight areas of progress, and to outline some 
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broad areas that should be considered if we are to address 
this issue.
Increasing awareness within data and digital health 
communities, and beyond
There is an opportunity for the health data research and 
digital health communities to be advocates for data-
deprived individuals, groups, and populations, so as to 
ensure that they are not left behind.3–5 Ultimately, 
funders, regulators, policy makers, and politicians need 
to make it a requirement for creators of digital health 
solutions to provide assurance that these technologies 
will be able to perform across different populations and 
settings. It is down to the health data research and 
digital health communities to ensure that these funders, 
regulators, policy makers, and politicians are educated 
in this regard. Efforts such as the Journal of the 
American Medical Informatics Association’s special 
focus issue on health informatics and health equity, 
published in 2019, are important steps in the right 
direction.29
Initiatives to increase transparency as to the 
composition of training datasets in artificial intelligence 
and machine learning models, such as the Data 
Nutrition Project and Datasheets for Datasets, could 
increase awareness and accountability and promote 
more responsible practice within data and digital health 
communities.30,31 Similarly, efforts to encourage people 
developing these models to transparently assess and 
report how representative the training dataset is of 
the model’s intended population and how well the 
model performs across relevant subgroups within that 
population, could facilitate the safe and appropriate 
application of such models in the real world.32,33 This 
information can be included in model facts labels or 
model cards, tools designed to communicate essential 
information about individual models to the user.
Transparent, effective communication to citizens
Transparently and effectively communicating to 
citizens as to how their data can directly contribute to 
making digital health solutions more safe, effective, 
and equitable is of utmost importance.34 Studies, 
including deliberative research and citizens’ juries, 
show that the more that people understand about how 
their data are used in health data research, the more 
they are willing to participate, by sharing their data, in 
such research.35–37 Additionally, it is essential to alleviate 
citizens’ privacy and confidentiality concerns,34 which 
have been shown to be substantial barriers that prevent 
people from participating in health data research.35–37 
Principally, alleviation of these concerns will be 
achieved by ensuring that all research activities are 
underpinned by effective governance systems, but also 
by transparently and effectively communicating to 
citizens the ways in which their data are being used and 
protected.38
Improving equity of digital access for data-gathering as 
well as health provision
An increasing proportion of digital health solutions are 
direct-to-citizen through smartphones, wearables, and 
other devices. There is, however, much inequity of access 
to these devices due to a range of factors including 
economic, education, and social. In the UK, in 2018, 
the Office for National Statistics reported that 10% of 
adults were internet non-users; this was associated with 
being older, female, from minority ethnic groups, and 
disabled.39 At the same time, the Lloyds Bank UK 
Consumer Index estimated that 8% of people in the UK 
did not have basic digital skills and a further 12% had 
only limited abilities.40 It is worth noting that there is the 
belief, among already-excluded groups, that they do not 
need to engage digitally; for example, 64% of households 
without internet access in the UK say that the reason 
they do not have internet access is that they do not 
need it.39 The impact that this paucity of digital access 
and engagement can have has been highlighted by the 
COVID-19 pandemic, during which digital health care 
has become central to the delivery of many services; a 
large number of people could be excluded from these 
digital health-care services.41
This paucity of digital access among a significant 
proportion of people is also relevant to health data 
poverty. Data from smartphone apps and wearables (the 
use of which is low among those who are not digitally 
engaged) will increase the scale and breadth of health 
data records to levels beyond the records kept by conven-
tional clinical systems. These sources will increasingly 
provide the data that train future data-driven technologies. 
A recent example is the effect of symptom-reporting 
smartphone apps such as the COVID Symptom Study 
app (ZOE). With over 4 million users worldwide, this app 
has been an exceptional real-time data-gathering exercise, 
supporting novel insights such as clustering of COVID-19 
symptoms and the prevalence of self-reported anosmia 
as a symptom.42 Crucially, the app also highlights the 
boundaries of generalisability outside the digital popula-
tion, such as underrepresentation of older people who 
have a much higher prevalence of anosmia for reasons 
not related to COVID-19.43
A more developed understanding is needed of the 
digital determinants of health; that is to say, the way in 
which social, cultural, and economic factors influence 
access to and outcomes of digital health solutions.44 Only 
through a thorough understanding of these factors will it 
be possible to take appropriate and effective action to 
ensure equitable access and outcomes regardless of age, 
sex, ethnicity, education, income, and geography.
Building inclusive and representative datasets to support 
equitable discovery and innovation in digital health care
Building datasets is probably the least exciting aspect of, 
but most important foundation for, digital health. We 
assert that the development and validation of digital health 
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solutions, especially those involving artificial intelligence 
and machine learning systems, requires investment in 
datasets that are: sufficiently representative of the whole 
population into which they will be deployed; of sufficient 
quantity and quality to provide confidence in any external 
validation process (and retraining if needed); and of 
appropriate accessibility, recognising the contrasting 
needs of development and training (high accessibility to 
anonymised data within a safe system)45 versus indepen-
dent evaluation and regulation (highly restricted access 
to data that is not available to developers but only to 
regulators and those providing independent testing and 
assurance of those algorithms). This requirement for 
datasets satisfying these criteria applies both to newly 
created digital health systems and when considering the 
deployment of an established system into a new setting or 
population; assurance of performance cannot be assumed 
on the basis of previous results in different settings or 
populations.
The creation of such datasets is a large investment. In 
the UK, Health Data Research UK is committed to 
“uniting the UK’s health data to enable discoveries that 
improve people’s lives”. It was recognised quickly that 
this aim could not be achieved simply through the use 
of research cohorts consisting of people who opt in to 
having their health data collected for the purposes of 
research. Such cohorts are valuable but lead to skewed 
populations, as seen in the example of UK Biobank.14 
More representative datasets are instead gathered 
through the use of routinely collected National Health 
Service data, such as through a number of Health Data 
Research Hubs and from Data Controllers who are 
working together as part of the Health Data Research 
Alliance, both of which are initiatives convened by Health 
Data Research UK.46 During the COVID-19 pandemic, 
this access to routinely collected data has meant that the 
UK has been well placed to address how the disease has 
affected different sectors of the population, including 
highlighting the worse outcomes seen in Black and 
Asian ethnic groups, and exploring the underlying 
causes for these findings. In other industries, datasets 
from a broad range of partici pants and environments are 
made publicly available to maximise accuracy of artificial 
intelligence and machine learning innovations, for 
example speech recognition and natural language 
processing datasets.47,48
The focus here, however, is not on what has been 
achieved in the UK or other countries with relatively 
mature health data resources, but rather on how much is 
still to do, and the concern that many vulnerable groups 
and whole parts of the world are being left behind. 
This will require concerted international data sharing 
initiatives as a powerful mechanism to address COVID-19 
and other global challenges. Among these is the 
International COVID-19 Data Research Alliance and 
Workbench,49 supported by the COVID-19 Therapeutics 
Accelerator, which has the vision to unite data from 
international clinical trials, biomedical research, and 
health research to enable discoveries that benefit all 
people, everywhere, by reducing the harm of the 
COVID-19 pandemic. This builds on the work of the 
Infectious Diseases Data Observatory and other inter-
national initiatives that assemble clinical, laboratory, and 
epidemiological data on a collaborative platform to be 
shared with the research and humanitarian communities. 
These are important first steps in developing and 
maintaining the integrity of a trustworthy international 
health data ecosystem.
Various philanthropic organisations fund international 
research initiatives. Data generated from these invest-
ments could be contracted to be shared, and targets for the 
adequate representation of the intended population be 
imposed as a condition of the grant; the funder could also 
dictate the level of open access required. By doing this, 
funders will enhance the original aim of the research, as 
well as the onward use of the resulting data in training 
datasets to better represent all people.
Looking to the future, together
Addressing health data poverty requires a collective 
approach of international stakeholders to enable the 
necessary engagement and investment, to share learning, 
and, wherever possible, to operate to common goals 
and standards. Solutions will vary between countries 
according to their needs, resources, and type of health 
system, but will need to consider core issues, such as 
ensuring that all research activities are underpinned by 
effective governance systems. This long-term investment 
in and stewardship of data requires a different mandate 
to the short-term drivers that predominate in academic, 
industry, health service, or political sectors. Funding 
models may vary but should ensure that data are available 
for the benefit of the population from which they were 
collected, with the opportunity for ongoing development 
and testing of digital health technologies that will 
improve the health of that population. Prioritisation of 
datasets will also vary by country but factors that should 
be considered will include local health needs, amenability 
of those needs to digital health solutions, and the facility 
For Health Data Research UK 
see https://www.hdruk.ac.uk/
For Infectious Diseases Data 
Observatory see https://www.
iddo.org
For Health Data Research 
Alliance see 
https://ukhealthdata.org
For COVID-19 Therapeutics 
Accelerator see https://www.
therapeuticsaccelerator.org
Search strategy and selection criteria
References for this Viewpoint were identified through 
searches of PubMed, Google Scholar, and Google search 
engine, with the search terms “artificial intelligence”, “big 
data”, “digital divide”, “digital health”, “digital health equity”, 
“equity”, “health disparities”, “health equity”, “health 
informatics”, and “machine learning”, from date of database 
inception until Nov 24, 2020. Searches were supplemented 
by manually screening the references of relevant articles. 
Only papers published in English language were reviewed. 
The final reference list was generated on the basis of 
originality and relevance to this Viewpoint.
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and cost of acquiring the data needed to support that 
digital health solution.
As the Ada Lovelace Institute reminds us: “Missing data 
matters: it can exacerbate inequalities on a societal scale. 
When that data is operationalised into algorithmic 
decision-making systems and AI, the social processes 
that produce racial inequality—mechanisms of power, 
economics, knowledge, culture and language—can be 
written into technologies with huge societal impacts.”50 
The barrier of missing data is assailable; now is the time 
to act if we are to counter the emerging digital health 
divide and build the data infrastructure that means that all 
parts of society can benefit from digital health solutions.
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